[Federal Register Volume 68, Number 216 (Friday, November 7, 2003)]
[Notices]
[Page 63115]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-28059]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
application listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent application.

Enhanced HIV-1 Vaccine Cytotoxic T Cell Epitope From Conserved Region 
of HIV-1 Reverse Transcriptase

Jay Berzofsky, Takahiro Okazaki (NCI).
U.S. Provisional Application No. 60/459,507 filed 31 Mar 2003 (DHHS 
Reference No. E-044-2003/0-US-01).
Licensing Contact: Michael Ambrose; 301/594-6565; 
[email protected].

    Polypeptides derived from the HIV-1 RT Catalytic site. Peptides are 
modified by replacement of certain key amino acid residues to increase 
binding to HLA-A2, the most common human class I HLA molecule. Such 
modified peptides are more immunogenic and can be used for further 
development of second-generation vaccines, therapeutics or diagnostic 
reagents. DNA encoding said modified polypeptides can be used as 
vaccines (naked DNA, bacterial or viral vector constructs).

Methods and Compositions for Selectively Enriching Microbes

Michael A. Grant (FDA/ORA).
U.S. Provisional Application No. 60/435,639 filed 20 Dec 2002 (DHHS 
Reference No. E-228-2002/0-US-01).
Licensing Contact: Michael Ambrose; 301/594-6565; 
[email protected].
    The described technology provides for the methods, reagents and 
kits for the specific enrichment of microbes for further identification 
and diagnosis with particular emphasis on E. coli O157:H7 and other E. 
coli.
    The technology details a 2-step process in which the primary sample 
is held under acid conditions to inhibit or kill competitor microbes 
within the sample. The acidic conditions can also contain selective 
agents such as phage or nutrient supplements for further selectivity. 
After a predetermined time, the sample is then incubated under 
unrestricted growth conditions for the enrichment of the remaining 
microbes. These are then carried through for further identification and 
potential diagnosis.
    The technology can be used to selectively enrich for potential 
medically important bacteria, especially E. coli O157:H7, other 
pathogenic E. coli, Shigella, and other species.

    Dated: October 24, 2003.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 03-28059 Filed 11-6-03; 8:45 am]
BILLING CODE 4140-01-P